Investors who Lost Money on Amphastar Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AMPH
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. for potential violations of federal securities laws. This follows the FDA's secondary complete response letter regarding Amphastar's generic teriparatide ANDA, AMP-015, after delays in submission.
February 21, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations. This follows an FDA response letter regarding their generic teriparatide ANDA, AMP-015, after submission delays.
The investigation by Levi & Korsinsky and the FDA's response letter suggest potential legal and regulatory challenges for Amphastar, likely impacting investor confidence and short-term stock performance negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100